National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Ibrutinib is indicated for the treatment of patients with chronic lymphocytic leukaemia who have received ≥1 prior therapy, or as a first-line treatment in the presence of del(17p) or TP53 mutation in patients not suitable for chemoimmunotherapy.

Rapid Review

Commenced Completed Outcome
07/11/2014 18/12/2014 Full Pharmacoeconomic Evaluation Recommended.

Pharmacoeconomic Evaluation

Commenced Completed Outcome
02/04/2015  01/10/2015 Reimbursement Not recommended

The cost effectiveness of ibrutinib (Imbruvica®) in the treatment of patients with CLL who have received ≥1 prior therapy, or as a first-line treatment in the presence of del(17p)/TP53 mutation in patients not suitable for chemo-immunotherapy, has not been demonstrated and therefore it is not recommended for reimbursement at the submitted price.

Summary

The HSE has approved reimbursement following confidential price negotiations.